Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies

Clinical Trial ID NCT00908167

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.	J Clin Oncol	2011	1.52
2	The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.	Ther Adv Hematol	2014	1.28
3	FLT3 inhibitors: a story of the old and the new.	Curr Opin Hematol	2011	1.09
4	FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.	Oncologist	2011	1.05
5	Exploiting cellular pathways to develop new treatment strategies for AML.	Cancer Treat Rev	2010	1.03
6	FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?	Cancer	2011	0.97
7	Ontogeny and sorafenib metabolism.	Clin Cancer Res	2012	0.92
8	Novel agents for the treatment of childhood acute leukemia.	Ther Adv Hematol	2015	0.87
9	The Biology and Targeting of FLT3 in Pediatric Leukemia.	Front Oncol	2014	0.83
10	Molecular therapeutic approaches for pediatric acute myeloid leukemia.	Front Oncol	2014	0.83
11	Targeted drug discovery for pediatric leukemia.	Front Oncol	2013	0.82
12	Advances in paediatric cancer treatment.	Transl Pediatr	2014	0.76